July 18, 2019 8:00pm

As the IBB closed UP +0.82% while the XBI closed UP +1.46%

What was today about, it's just speculation, though not a wild one!

With three (3) out of four (4) positive closes so far this week

Successful investors are effective in the long term because they admit their mistakes. As the world's greatest speculator, George Soros, said, "My system doesn't work by making valid predictions. It works by allowing me to recognize when I am wrong."

 

While many talk about the shift in alternating sentiment, I monitor the pulse and focus of possible outcomes!

 

Markets and indexes:

  • Thursday, the Dow closed barely up +3.12 points or +0.01% to 27,222.97;
  • Wednesday, the Dow closed down -115.78 points or -0.42% to 27,219.85
  • Tuesday, the Dow closed down -23.53 points or -0.09% to 27,335.63
  • Monday, the Dow closed up +27.13 points or +0.10% to 27,359.16;

 

  • Thursday, the S&P closed up +10.69  points or +0.36% at 2,995.11;
  • Wednesday, the S&P closed down -19.62 points or -0.65% at 2,984.42;
  • Tuesday, the S&P closed down -10.25 points or -0.34% at 3,004.04;
  • The S&P closed up +0.53 points or +0.02% at 3,014.30

 

  • Thursday, the NASDAQ was up +22.04 or +0.27% to 8,207.24;
  • Wednesday, the NASDAQ was down -37.59 or -0.46% to 8,185.21
  • Tuesday, the NASDAQ was down -35.29 or -0.43% to 8222.80
  • Monday, the NASDAQ was up +14.04 or +0.17% to 8258.18

 

Henry’omics:

The sector of my covered companies jumped as the oversold are now headed to be overbought as Q2 results start appearing!

Markets rose on Thursday after comments from a top Fed official that led to increasing bets that the central bank will ease monetary policy more aggressively.

The indexes turned around in the afternoon came after New York Federal Reserve President John Williams said the central bank needed to “act quickly” when the economy was slowing and rates were low. “It’s better to take preventative measures than to wait for disaster to unfold,” he said in a speech <CNBC>.

 

The percentage (%) indicators: 

  • Thursday’s range of the 27 upside was +0.40% (XON) to +6.71% (VSTM) while the 14 downside ranged from -0.07% (CLLS) to -10.18% (ADVM);
  • Wednesday’s range of the 23 upside was +0.12% (BMRN) to +17.92% (CUR after a 1 for 20 reverse +$0.0632) while the 20 downside ranged from -0.15% (VCEL) to -4.49% (ONVO);
  • Tuesday’s range of the 15 upside was +0.14% (KOOL) to +8.32% (CUR) while the 27 downside ranged from -0.06% (QURE) to -4.43% (BCLI);
  • Monday’s range of the 26 upside was +0.12% (RARE) to +11.79% (CLBS) while the 15 downside ranged from -0.05% (ONCE) to -4.88% ();

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday the IBB closed UP +0.82% while the XBI closed UP +1.46%
  • Wednesday the IBB closed up +0.19% while the XBI closed up +0.05%
  • Tuesday the IBB closed down -0.58% while the XBI closed down -0.84%
  • Monday the IBB closed up +0.53% while the XBI also closed up +0.36%

 

Thursday’s advance/decline line scenario of 45 covered companies:  

  • The open was positive with an A/D (A/D) line of 23/18 with x2flats and 2 acquired;
  • The mid-day was positive with an A/D Line of 22/20 with 1 flat and 2 acquired;
  • The close was positive with an A/D Line of 27/14 and 2 flat and 2 acquired;

 

Leading decliners were:

  • ReNeuron (RENE.L -$13.50 after Wednesday’s+$12.50 and Tuesday’s +$7.50);
  • Adverum Biotechnologies (ADVM -$1.56 after Wednesday’s -$0,56 and Tuesday’s +$0.43);
  • Vericel (VCEL -$0.27);
  • Brainstorm Cell Therapeutics (BCLI -$0.14);
  • Caladrius Biosciences (CLBS -$0.12)

Tuesday’s incliners:

  • Sage Therapeutics (SAGE +$4.15 after Wednesday’s +$1.41, Tuesday’s-$7.15 and Monday’s -$2.55);
  • Alnylam Pharmaceuticals (ALNY +$3.21 after Wednesday’s -$1.56, Tuesday’s +$1.45 and Monday’s+$1.25);
  • Ultragenyx (RARE +$3.03);
  • IONS Pharmaceuticals (IONS +$3.03)
  • uniQure (QURE +$2.15 after Wednesday’s +$2.83);

 

Upside volume stats:  to compare

  • Thursday: 2 out of the 27 upside had higher than the 3 month average volume;
  • Wednesday: 5 out of the 23 upside had higher than the 3 month average volume;
  • Tuesday: 4 out of the 15 upside had higher than the 3 month average volume;
  • Monday: 3 out of the 26 upside had higher than the 3 month average volume;

Downside volume stats: NOTICE

  • Thursday: 4 out of the 14 downside had higher than the 3 month average volume;
  • Wednesday: 1 out of the 20 downside had higher than the 3 month average volume;
  • Tuesday: 3 out of the 27 downside had higher than the 3 month average volume;
  • Monday: 3 out of the 15 downside had higher than the 3 month average volume;

 

2 flat – ADRO and AGTC with 2 acquired (AST & OSIR) and the Spark Therapeutics’ (ONCE) acquisition by Roche still being delayed

 

July’s sessions and the beginning of Q3:

Thursday closed POSITIVE with 14 decliners, 27 advancers, 2 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 23 advancers, 0 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 27 decliners, 15 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 22 decliners, 21 advancers, 0 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 14 advancers, 3 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 25 decliners, 16 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 13 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 24 decliners, 18 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday was a holiday;

Wednesday closed POSITIVE with 10 decliners, 31 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 30 decliners, 11 advancers, 2 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.